LIDE Biotech

Overview

LIDE Biotech is an oncology-focused preclinical contract research organization founded in 2011 by overseas returnees. The company operates AAALAC-accredited laboratories in China and provides preclinical models and services to global pharmaceutical and biotech clients.

Core Capabilities

Preclinical Models & Platforms:

• 2300+ patient-derived xenograft (PDX) models across 50+ cancer types, including 400+ pre-treated and 370+ drug-resistant models
• 120+ cell line-derived xenograft (CDX) models
• Orthotopic, syngeneic, humanized, and autoimmune disease models
• Ex vivo models including 3D spheroid and organoid assays, conditionally reprogrammed (CR) cells, and co-culture assays for immuno-oncology
• MiniPDX® 7-day in vivo organoid assay with IO-FIVE® platform for immuno-oncology applications

Analytical & Genomic Services:

• In-house multi-omics analysis
• OncoVee™ K-Cell 1000 Cell Kit
• Transcription analysis and bioinformatics
• Sequencing and functional genomic imaging (FGI)
• Multiplex tissue imaging

Therapeutic Focus Areas:

• Preclinical oncology studies
• Immuno-oncology (IO) platform
• Hematological malignancies and blood cancers
• Drug-resistant cancer models
• ADC (antibody-drug conjugate) development acceleration

Research Phases Supported:

• Target identification and HIT discovery
• Lead optimization and preclinical validation
• Clinical testing and biomarker identification

Differentiation

LIDE emphasizes a "preclinical focus, clinical mindset" approach, leveraging tools designed to bring preclinical studies as close as possible to clinical relevance. The company maintains global leadership with local support, offering verified quality on Scientist.com and commitment to operational excellence.